Alexion Pharmaceuticals Inc. is looking to the second half of 2018 as the target for regulatory filings in the U.S., EU and Japan after ALXN-1210, its long-acting C5 complement inhibitor, hit noninferiority to Soliris (eculizumab) across co-primary and the four key secondary endpoints in the pivotal phase III Study 301 in complement inhibitor treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH).